

In the claims:

1. (Canceled)
2. (Previously Presented) The composition of claim 24, wherein said amount is at least about 10% by weight of said composition.
3. (Canceled)
4. (Previously Presented) The composition of claim 24, wherein said amount is at least about 10% by weight of said composition and wherein said doubling time is extended by a factor of at least about two.
5. (Previously Presented) The composition of claim 24, wherein said amount is at least about 30% by weight of said composition and wherein said doubling time is extended by a factor of at least about two.
6. (Previously Presented) The composition of claim 24, wherein said amount is at least about 20% by weight of said composition and wherein said doubling time is extended by a factor of at least about three.
7. (Original) The composition of claim 4, wherein said doubling time is extended by a factor of at least about four.
- 8-14. (Canceled)
15. (Previously Presented) The composition of claim 24, wherein a single dose of said composition provides extended release of at least one of said radiosensitizers over a period of at least about 15 days.
16. (Previously Presented) The composition of claim 24, wherein a single dose of said composition provides extended release of at least one of said radiosensitizers over a period of at least about 30 days.
- 17-23. (Canceled)
24. (Previously Presented) A composition suitable for administration to a patient for treating a neoplasm, said composition comprising:

(a) a biocompatible polymer having phosphorous-based linkages; and

(b) one or more radiosensitizers in an aggregate amount equal to at least five percent by weight of said composition,

wherein a single dose of said composition provides extended release of at least one of said radiosensitizers over a period of at least about one day, and

wherein said composition is effective to inhibit the growth of said neoplasm upon

(i) administration of said composition to said patient such that said composition is in at least partial contact with said neoplasm or tissue surrounding the site of said neoplasm, and (ii) subsequent treatment of said patient with electromagnetic radiation; wherein said inhibition of said growth of said neoplasm is measured as a delay in doubling time as compared to no treatment; and wherein the composition is formulated in microspheres having a mean diameter of less than about 250 microns.

25. (Previously Presented) The composition of claim 24, wherein the mean diameter of said microspheres is less than about 100 microns.


26. (Canceled)

27. (Previously Presented) The composition of claim 24, wherein said microspheres further comprise a pharmaceutically acceptable carrier.

28. (Previously Presented) The composition of claim 24, wherein said polymer is biodegradable.


29-35. (Canceled)

36. (Previously Presented) The composition of claim 24, wherein said polymer has one or more monomeric units represented by the following Formula VI:



Formula VI

wherein Z1 and Z2, respectively, for each independent occurrence is:



wherein, independently for each occurrence of said monomeric unit:

Q1, Q2 ... Qs, each independently, represent -O- or -N(R7);

X1, X2 ... Xs, each independently, represent -O- or -N(R7);

R7 represents -H, aryl, alkenyl or alkyl;

the sum of t1, t2 ... ts is an integer and equal to at least one or more;

Y1 represents -O-, -S- or -N(R7)-;

x and y are each independently integers from 1 to about 1000 or more;

L1 represents a divalent branched or straight chain or cyclic aliphatic group or divalent aryl group;

M1, M2 ... Ms each independently, represents a divalent aliphatic moiety having from 1 to about 7 carbon atoms;


R8 represents -H, alkyl, -O-alkyl, -O-cycloalkyl, aryl, -O-aryl, heterocycle, -O-heterocycle, or -N(R9)R10;

R9 and R10, each independently, represent a hydrogen, an alkyl, an alkenyl, - $(CH_2)_m$ -R11, or R9 and R10, taken together with the N atom to which they are attached complete a heterocycle having from 4 to about 8 atoms in the ring structure;

m represents an integer in the range of 0-10; and

R11 represents -H, alkyl, aryl, cycloalkyl, cycloalkenyl, heterocycle or polycycle.

37. (Original) The composition of claim 36, wherein said monomeric units comprise at least about 95 percent of the repeating units of said polymer.
38. (Original) The composition of claim 37, wherein the average molar ratio of (x or y):L1, when  $t_s$  is equal to one, is from about 10:1 to about 4:1.
39. (Canceled)
40. (Original) The composition of claim 37, wherein each Q1, Q2 ... Qs and each X1, X2 ... Xs of each of said monomeric units of said polymer is O and the sum of  $t_1, t_2 \dots t_s$  equals one for each of Z1 and Z2.
- 41-42. (Canceled)
43. (Original) The composition of claim 36, wherein each of Z1 and Z2 is represented by:



wherein the configuration of the chiral carbons independently for each unit x for Z1 and unit y for Z2 is either D for  $t_1$  and L for  $t_2$ , or L for  $t_1$  and D for  $t_2$ .

44. (Original) The composition of claim 43, wherein each of Y1 is O and L1 is -CH(CH<sub>3</sub>)CH<sub>2</sub>-.
- 45-59. (Canceled)

60. (Currently Amended) A kit containing a drug delivery system, comprising (a) a composition as in claim ~~claims~~ 24, ~~26~~, or 27, and (b) instructions for administering said composition to a subject with a neoplasm and a treatment of said subject with electromagnetic radiation following said administration.